Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 11:02AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-14.70 Insider Own15.22% Shs Outstand1.33M Perf Week6.06%
Market Cap6.98M Forward P/E- EPS next Y-3.73 Insider Trans0.00% Shs Float1.13M Perf Month-30.46%
Income-15.41M PEG- EPS next Q-1.91 Inst Own19.20% Short Float2.58% Perf Quarter19.59%
Sales14.50M P/S0.48 EPS this Y59.56% Inst Trans-11.23% Short Ratio0.03 Perf Half Y-20.75%
Book/sh0.04 P/B136.65 EPS next Y64.48% ROA-107.34% Short Interest0.03M Perf Year-65.57%
Cash/sh0.74 P/C7.05 EPS next 5Y- ROE-311.34% 52W Range2.73 - 48.79 Perf YTD-57.80%
Dividend Est.- P/FCF- EPS past 5Y-18.88% ROI-912.01% 52W High-89.24% Beta8.03
Dividend TTM- Quick Ratio0.28 Sales past 5Y59.81% Gross Margin55.68% 52W Low92.31% ATR (14)0.69
Dividend Ex-Date- Current Ratio0.28 EPS Y/Y TTM49.20% Oper. Margin-131.52% RSI (14)42.32 Volatility6.93% 12.13%
Employees154 Debt/Eq42.00 Sales Y/Y TTM-11.93% Profit Margin-106.27% Recom1.00 Target Price7.12
Option/ShortNo / Yes LT Debt/Eq32.80 EPS Q/Q72.68% Payout- Rel Volume0.22 Prev Close5.20
Sales Surprise-26.64% EPS Surprise41.67% Sales Q/Q-22.26% EarningsNov 14 AMC Avg Volume1.09M Price5.25
SMA20-2.16% SMA50-30.61% SMA200-36.28% Trades Volume67,948 Change0.96%
Feb-22-24 12:39PM
Feb-15-24 08:00AM
Feb-12-24 09:24AM
Feb-06-24 07:30AM
Jan-08-24 07:30AM
07:30AM Loading…
Dec-11-23 07:30AM
Nov-30-23 08:51AM
Nov-29-23 01:04PM
Nov-14-23 04:05PM
Nov-09-23 04:30PM
01:51PM Loading…
Nov-03-23 01:51PM
Nov-02-23 05:00PM
Oct-31-23 08:00AM
Oct-26-23 07:30AM
Oct-24-23 07:30AM
Oct-12-23 08:50AM
Oct-11-23 01:47PM
Oct-05-23 07:30AM
Oct-04-23 07:30AM
Oct-02-23 07:30AM
Aug-23-23 09:55AM
Aug-16-23 04:05PM
Aug-14-23 05:06PM
08:31PM Loading…
Aug-10-23 08:31PM
Jun-15-23 12:55PM
Jun-13-23 08:50AM
Jun-10-23 04:31PM
Jun-09-23 01:04PM
Jun-08-23 05:25PM
Jun-06-23 04:30PM
May-16-23 01:19PM
May-09-23 07:30AM
May-01-23 04:09PM
Apr-05-23 06:36AM
Apr-04-23 12:30PM
Mar-30-23 04:05PM
Mar-08-23 07:30AM
Mar-01-23 07:30AM
Feb-21-23 04:05PM
Jan-27-23 07:05AM
Jan-20-23 07:30AM
Jan-09-23 04:45PM
Jan-05-23 08:10AM
Jan-04-23 07:30AM
Dec-20-22 04:15PM
Dec-16-22 07:30AM
Dec-15-22 07:30AM
Nov-28-22 04:47PM
Nov-27-22 07:49AM
Nov-22-22 07:30AM
Aug-26-22 07:30AM
Aug-22-22 04:05PM
Aug-15-22 07:30AM
Aug-09-22 08:00AM
Jul-14-22 08:00AM
Jun-29-22 08:00AM
Jun-14-22 08:30AM
May-26-22 08:00AM
May-21-22 08:35AM
May-16-22 04:05PM
Apr-28-22 07:30AM
Apr-26-22 08:26AM
Mar-31-22 04:05PM
Mar-08-22 09:11AM
Mar-03-22 08:00AM
Mar-02-22 08:00AM
Feb-24-22 08:00AM
Jan-27-22 07:30AM
Jan-19-22 01:27PM
Dec-14-21 01:11PM
Dec-09-21 07:30AM
Dec-03-21 07:30AM
Nov-15-21 04:05PM
Nov-09-21 07:30AM
Oct-22-21 07:30AM
Oct-20-21 11:17AM
Oct-19-21 04:00PM
Oct-18-21 07:30AM
Oct-13-21 10:59AM
Sep-29-21 07:03AM
Sep-23-21 12:28PM
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huntsman Ronald KirkChief Executive OfficerJun 20Buy0.5314,0007,42086,521Jun 20 09:58 PM
Huntsman Ronald KirkChief Executive OfficerJun 16Buy0.5415,0008,05072,521Jun 20 06:10 AM
Huntsman Ronald KirkChief Executive OfficerJun 15Buy0.50211057,521Jun 20 06:10 AM
Huntsman Ronald KirkChief Executive OfficerJun 14Buy0.4910,0004,90057,500Jun 15 07:15 PM